Perspectives
Biosimilar Pipeline Quarterly Update: March 2023
Critical updates in an ever-changing environment
March 27, 2023This quarterly pipeline wrap-up provides a review of newly approved biosimilars, an update on the biosimilar pipeline and news of note on biosimilars in the approval process. See separate articles for updates on traditionaldrugs, specialty drugs and cell/gene therapies.
New Drug Information
- None
New Indications
- None
Biosimilar Product Approvals in the Past Twelve Months
Generic Name | Brand Name | Reference
Product |
Manufacturer | Indication(s) | Route of Administration | Month Approved |
adalimumab-aacf | Idacio® | Humira® | Fresenius | Autoimmune | SC | December 2022 |
insulin glargine-aglr
Interchangeable biosimilar |
Rezvoglar® | Lantus® | Eli Lilly | Diabetes | SC | November 2022 |
bevacizumab-adcd | Vegzelma® | Avastin® | Celltrion | Oncology | IV | September 2022 |
pegfilgrastim-fpgk | Stimufend® | Neulasta® | Fresenius Kabi | Neutropenia | IV or SC | September 2022 |
adalimumab-bwwd 100mg/mL | Hadlima® HC | Humira® | Samsung Bioepis/ Organon | Autoimmune | SC | August 2022 |
ranibizumab-eqrn
Interchangeable biosimilar |
Cimerli® | Lucentis® | Coheres biosciences/bioeq | Age-related macular degeneration | Injection into the eye | August 2022 |
pegfilgrastim-pbbk | Fylnetra™ | Neulasta® | Amneal/ Kashiv (Adello) | Neutropenia | IV or SC | May 2022 |
bevacizumab-maly | Alymsys™ | Avastin® | mAbxience/ Insud Pharma/ Amneal | Oncology | IV | April 2022 |
Biosimilar Pipeline
Generic Name | Brand Name | Manufacturer | Indication(s) | Route of Administration | Anticipated Approval date* |
Oncology | |||||
SB8 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Samsung Bioepis/ Merck | Oncology | IV | 2023 |
FKB238 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Centus Biotherapeutics | Oncology | IV | 2023 |
BAT-1706 (bevacizumab biosimilar) | N/A (Avastin® biosimilar) | Bio-thera solutions | Oncology | IV | 2023 |
HLX02 (trastuzumab biosimilar) | N/A (Herceptin® biosimilar) | AccordBioPharma (Intas)/ Shanghai Henlius Biotech | Oncology | IV | 2023 |
Blood Modifiers | |||||
pegfilgrastim | Lupifil-p® (Neulasta® biosimilar) | Lupin | Neutropenia | SC | 2023 |
pegfilgrastim | Lapelga® (Neulasta® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
TX01 (filgrastim biosimilar) | N/A (Neupogen® biosimilar) | Tanvex BioPharma | Neutropenia | SC | 2023 |
filgrastim | Grastofil® (Neupogen® biosimilar) | Apotex/Accord | Neutropenia | SC | 2023 |
Ophthalmology | |||||
ranibizumab | Xlucane® (Lucentis® biosimilar) | Xbrane & Bausch | Age-related macular degeneration | Injection into the eye | 2023 |
MYL1701P (aflibercept) | N/A (Eylea® biosimilar) | Mylan | Age-related macular degeneration | Injection into the eye | 2023 |
Autoimmune | |||||
CTP17 (adalimumab) | Yuflyma® (Humira® biosimilar) | Celltrion | Autoimmune | SC | 2023 |
MSB11456 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Fresenius | Autoimmune | IV/SC | 2Q2023 |
BIIB800 (tocilizumab) | N/A (Actemra® IV/SC biosimilar) | Biogen | Autoimmune | IV/SC | 10/2023 |
ABP654
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Amgen | Autoimmune | SC | 2H2023 |
AVT04
(ustekinumab) |
N/A (Stelara® SC biosimilar) | Alvogen/Alvotech | Autoimmune | SC | 2H2023 |
Immunosuppressant | |||||
PB006 (natalizumab) | N/A (Tysabri® biosimilar) | Sandoz-Polpharma | Multiple sclerosis | IV | 5/2023 |
Bone Health | |||||
GP2411 (denosumab) | N/A (Prolia® biosimilar) | Sandoz | Osteoporosis | SC | 12/2023 |
Related news
Perspectives
April 23, 2024
Expert Clinical Network Insights: April 2024
A look into our Expert Clinical Network (ECN) – part of Prime/MRx’s value-based approach to medical and pharmacy benefit management that offers access to more than 175 national and world-renowned key opinion leaders in multiple disease categories who provide expertise on challenging prior authorization case reviews, peer-to-peer discussions, drug policy development and formulary guidance
Perspectives
April 23, 2024
April Fraud Focus – How to prioritize drug safety at home
While ensuring drug safety is often considered the responsibility of pharmaceutical industry players,…
Perspectives
April 19, 2024
AMCP 2024: Behind the Research with Prerak Parikh
Parikh, director of medical pharmacy strategy at Prime/MRx, shares the latest on interchangeable biosimilars